title: Risk of developing fibroadenoma with the use of cyclosporine A in renal transplant recipients.
abstract: To investigate the effect of cyclosporine A (Cyc A) on the development of fibroadenomas, 30 renal transplant patients and 20 chronic renal failure patients on dialysis were breast examined with ultrasonography and/or mammography. Of the renal transplant patients, 17 were receiving Cyc A-based combination therapy for immunosuppression. All patients were female with the age range of 29.7+/-9.2 years in the transplant group and 33.95+/-9.91 in the dialysis group. Eight of the 17 patients receiving Cyc A had fibroadenomas, 5 of them having bilateral lesions. None of the other patients, those on dialysis and on non-Cyc A combination therapy had fibroadenomas. A significant difference for fibroadenoma incidence in patients receiving Cyc A combination immunosuppression was found.
authors.affiliation: Department of Radiology, Faculty of Medicine, Cukurova University, Balcali Adana, Turkey. fbinokay@cu.edu.tr
authors.forename: Figen
authors.initials: F
authors.lastname: Binokay
authors.forename: Mustafa
authors.initials: M
authors.lastname: Balal
authors.forename: Erkan
authors.initials: E
authors.lastname: Demir
authors.forename: Saime
authors.initials: S
authors.lastname: Paydas
authors.forename: Sureyya
authors.initials: S
authors.lastname: Soyupak
authors.forename: Yasar
authors.initials: Y
authors.lastname: Sertdemir
authors.forename: Erol
authors.initials: E
authors.lastname: Akgul
mesh_terms: D000328:Adult; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D003430:Cross-Sectional Studies; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D018226:Fibroadenoma / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000379:methods; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D018570:Risk Assessment; D014181:Transplantation Immunology / Q000502:physiology
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine